MedTrace Logo

The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events

NCT05421286 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 991

Last updated 2025-04-11

No results posted yet for this study

Summary

MISTRAL (Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications, antimicrobial drug resistance, and unresponsiveness to therapeutic HIV-1 vaccination) is a 5-year EU Horizon 2020 project, running from 1/1/2020 - 31/12/2025.

The project is led by Fundacio Privada Institut de Recerca de la Sida-Caixa CAIXA in Barcelona and aims to explore the gut microbiota in relation to HIV-1, seeking microbiome biomarkers to support development of interventions that mitigate infection and enhance response to vaccines and therapies.

If successful, MISTRAL will benefit millions of human beings living with, or at risk of acquiring HIV-1 infection, and will produce novel concepts and technical innovations applicable to other human diseases. By doing that, MISTRAL will help to unlock the full clinical potential of the human microbiome to stratify patient outcomes and will irreversibly bring microbiome science closer to clinical practice

Conditions

Sponsors & Collaborators

  • IrsiCaixa

    collaborator OTHER

  • Horizon 2020 - European Commission

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Jens Lundgren, Professor · CHIP, Rigshospitalet

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-28
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Belgium
  • Croatia
  • Czechia
  • Denmark
  • Germany
  • Israel
  • Italy
  • Luxembourg
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05421286 on ClinicalTrials.gov